Three-Dimensional Quantitative Structure−Activity Relationship (3D-QSAR) Models for a Novel Class of Piperazine-Based Stromelysin-1 (MMP-3) Inhibitors: Applying a “Divide and Conquer” Strategy
Authors:
- 13 October 2001
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (23) , 3849-3855
Abstract
Three-dimensional quantitative structure-activity relationship (3D-QSAR) models have been obtained using comparative molecular field analysis (CoMFA) for a novel series of piperazine-based matrix metalloproteinase inhibitors (MMPIs). The crystal structure of stromelysin-1 (MMP-3) was used to identify regions of the enzyme and inhibitors where steric and electrostatic effects correlate strongly with biological activity. A training set composed of a subset of inhibitors (#10-35), which differed only with regards to the substituent (n-alkyl, amide, carbamide and sulfonamide) on the piperazine distal nitrogen, yielded the most predictive CoMFA model, with r(2) values of 0.592 (cross-validated) and 0.989 (conventional); this model was further validated using test compounds from two inhibitor subsets. Investigation of various ligand conformations, inhibitor subsets, alignment schemes and partial charge formalisms was required to obtain satisfactory models. The greatest success was achieved by incorporating inertial alignment together with manual adjustment of the enzyme-docked inhibitors to ensure complementarity between the inhibitors' substituent conformations and the structural characteristics of the MMP-3 S1-S2' binding pockets. Key insights into the structure-activity relationship (SAR) obtained from this analysis for this inhibitor set are in agreement with experimentally observed data on stromelysin-1 biological activity and binding-site topology. In particular, the present study sheds new light on the steric and electrostatic requirements for ligand binding to the partly solvent-exposed S1-S2' area.Keywords
This publication has 13 references indexed in Scilit:
- Design and Synthesis of Piperazine-Based Matrix Metalloproteinase InhibitorsJournal of Medicinal Chemistry, 2000
- Design and Therapeutic Application of Matrix Metalloproteinase InhibitorsChemical Reviews, 1999
- Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivityProtein Science, 1998
- Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptorThe EMBO Journal, 1998
- Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in RabbitsJournal of Medicinal Chemistry, 1997
- Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding.Proceedings of the National Academy of Sciences, 1996
- Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzymeProtein Science, 1995
- Inhibition of matrix metalloproteinases by N-carboxyalkyl peptidesJournal of Medicinal Chemistry, 1993
- Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteinsJournal of the American Chemical Society, 1988
- Iterative partial equalization of orbital electronegativity—a rapid access to atomic chargesTetrahedron, 1980